The impending expiration of blockbuster biologic patents is opening the door for biosimilar entry, accelerating affordability and broadening treatment access https://www.einpresswire.com/article/833505102/biosimilars-and-biologics-market-growth-driven-by-patent-expiries-innovation-datam-intelligence